101.01
+0.40%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lantheus Holdings
From its filings with the US Securities and Exchange Commission
Lantheus Holdings is based in Bedford, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LNTH. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 31 December 2025, it reported revenue of $1.54bn and net income of $233.6m. At that date it held total assets of $2.23bn and shareholders' equity of $1.09bn. By region, UNITED STATES accounted for 94.6%, followed by Rest of world at 5.4%.
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically, and contract development and manufacturing organization (“CDMO”) revenue generated by Evergreen.
Our commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings. We believe that our diagnostic products provide information that enables HCPs to better detect and characterize, or rule out, disease, with the potential to achieve better patient outcomes, reduce patient risk, and limit overall costs.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 25 Jun 2015
- Employees
- 1,193
- Website
- lantheus.com ↗
- Head office
- 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD, MA, 01730
- Incorporated in
- DE
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Mary HeinoExecutive Chairman of the Board, Interim Executive Officer, since 2013$787,596
- Mr. Robert MarshallChief Financial Officer, Treasurer$5.4m
- Ms. Jamie SpaethChief People Officer
- Mr. Daniel NiedzwieckiChief Administrative Officer, General Counsel, Corporate Secretary$4.4m
- Dr. Jean-Claude ProvostChief Scientific Officer$3.5m
- Ms. Amanda MorganChief Commercial Officer$2.8m
- Ms. Julie MchughLead Independent Director$483,406
- Ms. Minnie Baylor-HenryIndependent Director$483,406
- Dr. Gerard BerIndependent Director$475,906
- Ms. Julie EastlandIndependent Director$284,682
- Mr. Samuel LenoIndependent Director$494,656
- Mr. Heinz MaeusliIndependent Director$482,156
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 38
- Social
- 70
- Governance
- 30
- Direct emissions (scope 1)
- 12,082 t
- Energy emissions (scope 2)
- 78 t
- Women in the workforce
- 49%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lantheus Holdings Inc has several key strengths that contribute to its competitive advantage in the market. These strengths include:
Weaknesses
- However, Lantheus Holdings Inc also faces certain weaknesses that need to be addressed in order to maintain its growth and profitability:
Opportunities
- Lantheus Holdings Inc operates in a dynamic market with several opportunities that can be leveraged to drive future growth:
Threats
- Despite its strong position, Lantheus Holdings Inc needs to be aware of potential threats that may impact its operations and market share:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.